articleThe LancetJul 1, 2008Closed access

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

AMAlexander M.M. EggermontSSStefan SuciuMSMario SantinamiATAlessandro TestoriWHWim H.J. Kruit

Erasmus MC · European Organisation for Research and Treatment of Cancer · +12 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

642
total citations
FWCI
26.81
Percentile
100%
References
25
Citations per year

Authors

16

Topics & keywords

Topics
Keywords
  • Medicine
  • Adjuvant
  • Melanoma
  • Stage (stratigraphy)
  • Internal medicine
  • Pegylated interferon
  • Adjuvant therapy
  • Oncology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.